Literature DB >> 19214078

A pilot study of observational motor assessment in infants and toddlers with spinal cord injury.

Christina L Calhoun1, John P Gaughan, Ross S Chafetz, M J Mulcahey.   

Abstract

PURPOSE: To examine the reliability of an observational movement assessment in infants and children with spinal cord injury (SCI) by evaluating interrater agreement of joint actions assessed in the International Standards for Neurological Classification of Spinal Cord Injury using the Active Movement Scale testing technique and scoring criteria.
METHODS: A series of 5 consecutive children with SCI aged 12 months to 4 years were enrolled in this pilot study to evaluate interrater agreement of observational movement.
RESULTS: There was high agreement of examination scores for unimpaired muscles and completely paralyzed muscles in strength comparisons between the 2 examiners. There was much less agreement of examination scores of partially intact muscles.
CONCLUSION: Observational movement assessment may be one component of assessing motor function in infants and toddlers with SCI, but additional work must be done.

Entities:  

Mesh:

Year:  2009        PMID: 19214078     DOI: 10.1097/PEP.0b013e31818f5bbd

Source DB:  PubMed          Journal:  Pediatr Phys Ther        ISSN: 0898-5669            Impact factor:   3.049


  2 in total

1.  Interrater Reliability of the Pediatric Neuromuscular Recovery Scale for Spinal Cord Injury.

Authors:  Andrea L Behrman; Shelley A Trimble; Laura C Argetsinger; MacKenzie T Roberts; M J Mulcahey; Lisa Clayton; Mary E Gregg; Doug Lorenz; Elizabeth M Ardolino
Journal:  Top Spinal Cord Inj Rehabil       Date:  2019

2.  Muscle Activation Patterns During Movement Attempts in Children With Acquired Spinal Cord Injury: Neurophysiological Assessment of Residual Motor Function Below the Level of Lesion.

Authors:  Darryn A Atkinson; Laura Mendez; Natalie Goodrich; Sevda C Aslan; Beatrice Ugiliweneza; Andrea L Behrman
Journal:  Front Neurol       Date:  2019-12-20       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.